<DOC>
	<DOCNO>NCT01865331</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability pharmacokinetic ( exposure trial drug body ) pharmacodynamic ( effect investigate drug body ) characteristic insulin degludec ( insulin 454 ) insulin degludec/insulin aspart ( IDegAsp ) 50 - formerly SIAM ) , explorative formulation , similar propose commercial formulation , healthy male Japanese subject .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Pharmacodynamic Characteristics Explorative Formulations Insulin Degludec IDegAsp 50 Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Japanese passport holder Japaneseborn parent Body mass index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Fasting blood glucose equal 6 mmol/L Healthy male subject , consider generally healthy base assessment medical history , physical examination clinical laboratory data screening , assessment medical history , physical exjudged Investigator The receipt investigational drug within 3 month prior trial Subjects history significant multiple drug allergy know allergy trialproduct medicine chemically related trial product , judge Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>